NASDAQ:TRVN Trevena (TRVN) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free TRVN Stock Alerts $0.44 +0.02 (+4.76%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4550-Day Range$0.35▼$0.5952-Week Range$0.30▼$3.28Volume112,979 shsAverage Volume170,569 shsMarket Capitalization$8.06 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Trevena alerts: Email Address Trevena MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,945.5% Upside$9.00 Price TargetShort InterestHealthy0.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.28) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevena has only been the subject of 1 research reports in the past 90 days.Read more about Trevena's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.33% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently decreased by 47.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for TRVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 13.56% of the stock of Trevena is held by institutions.Read more about Trevena's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($1.28) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Trevena's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Trevena Stock (NASDAQ:TRVN)Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Read More TRVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVN Stock News HeadlinesApril 30, 2024 | americanbankingnews.comTrevena (NASDAQ:TRVN) Research Coverage Started at StockNews.comApril 28, 2024 | finance.yahoo.comTrevena, Inc. (TRVN)May 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.April 28, 2024 | benzinga.comTrevena Stock (NASDAQ:TRVN), Analyst Ratings, Price Targets, PredictionsApril 21, 2024 | msn.comTrevena Cross free art exhibition featuring local artistsApril 18, 2024 | msn.comTrevena (TRVN) Price Target Decreased by 7.69% to 6.12April 5, 2024 | morningstar.comTrevena Inc TRVNApril 4, 2024 | msn.comDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In BulgariaMay 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.April 3, 2024 | msn.comTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital EnvironmentApril 2, 2024 | benzinga.comRecap: Trevena Q4 EarningsApril 1, 2024 | globenewswire.comTrevena Reports Fourth Quarter 2023 Results and Provides Corporate UpdateMarch 16, 2024 | msn.comTrevena Cross cafe reopening as the Palm Tree BistroMarch 8, 2024 | msn.comThe Palm Tree Bistro at Trevena Cross Nurseries reopeningFebruary 22, 2024 | benzinga.comTrevena Stock (NASDAQ:TRVN), Short Interest ReportJanuary 10, 2024 | msn.comTrevena files to sell 2.78M shares for holdersDecember 28, 2023 | finance.yahoo.comTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseDecember 28, 2023 | finance.yahoo.comTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseDecember 27, 2023 | msn.comTrevena announces private placement and warrant exerciseDecember 27, 2023 | markets.businessinsider.comTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseDecember 27, 2023 | finance.yahoo.comTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseDecember 16, 2023 | msn.comFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’December 15, 2023 | msn.comFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'December 4, 2023 | finance.yahoo.comTrevena Awarded OLINVYK Agreement with Premier, Inc.December 4, 2023 | finance.yahoo.comTrevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual MeetingNovember 30, 2023 | finance.yahoo.comTrevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn InjuriesNovember 17, 2023 | finance.yahoo.comTrevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/07/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,945.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,290,000.00 Net MarginsN/A Pretax Margin-1,289.25% Return on Equity-1,018.15% Return on Assets-98.93% Debt Debt-to-Equity Ratio8.35 Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$3.12 million Price / Sales2.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-1.00Miscellaneous Outstanding Shares18,320,000Free Float17,881,000Market Cap$8.06 million OptionableOptionable Beta1.11 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Carrie L. Bourdow (Age 61)President, CEO & Chairman Comp: $1MMr. Barry Shin (Age 52)Executive VP, COO & CFO Comp: $670.02kDr. Mark A. Demitrack M.D. (Age 66)Senior VP & Chief Medical Officer Comp: $690.32kDr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. Joel SolomonVP, General Counsel & Chief Compliance OfficerMr. Michael CatalanoVice President of MarketingMr. Robert T. Yoder (Age 58)Senior VP, Chief Business Officer & Head of Commercial Operations Comp: $490.64kMs. Patricia M. Drake (Age 58)Senior VP & Chief Commercial Officer More ExecutivesKey CompetitorsCan-Fite BioPharmaNYSE:CANFVaccinexNASDAQ:VCNXPasithea TherapeuticsNASDAQ:KTTAHepion PharmaceuticalsNASDAQ:HEPAAyala PharmaceuticalsNASDAQ:ADXSView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 797,714 shares on 2/13/2024Ownership: 4.614%View All Institutional Transactions TRVN Stock Analysis - Frequently Asked Questions Should I buy or sell Trevena stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks. What is Trevena's stock price target for 2024? 1 equities research analysts have issued 12 month price targets for Trevena's stock. Their TRVN share price targets range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 1,945.5% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts. How have TRVN shares performed in 2024? Trevena's stock was trading at $0.7221 at the start of the year. Since then, TRVN stock has decreased by 39.1% and is now trading at $0.44. View the best growth stocks for 2024 here. Are investors shorting Trevena? Trevena saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 58,900 shares, a decrease of 47.8% from the March 31st total of 112,800 shares. Based on an average trading volume of 203,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company's shares are sold short. View Trevena's Short Interest. When is Trevena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TRVN earnings forecast. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings results on Monday, April, 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The biopharmaceutical company earned ($0.08) million during the quarter, compared to analysts' expectations of $0.09 million. When did Trevena's stock split? Shares of Trevena reverse split before market open on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX). How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRVN) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBiden replacement revealed?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon Musk Secret Crypto Plot ExposedCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.